Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 553 Specimen Handling 466 Carboplatin 442 Magnetic Resonance Spectroscopy 430 Cyclophosphamide 415 Cisplatin 397 Radiotherapy 312 Gemcitabine 309 Bevacizumab 309 Paclitaxel 295 Biopsy 259 Drug Therapy 249 Capecitabine 242 fludarabine 239 Oxaliplatin 239 Nivolumab 225 venetoclax 219 Injections 213 Docetaxel 205 Fluorouracil 203 Dexamethasone 186 Radiosurgery 172 Rituximab 158 Pemetrexed 153 Standard of Care 147 durvalumab 143 Leucovorin 139 atezolizumab 138 toripalimab 134 tislelizumab 134

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡